Patents by Inventor Koen Vandyck

Koen Vandyck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds targeting PRMT5
    Patent number: 11198699
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: December 14, 2021
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
  • MODULATORS OF THR-BETA AND METHODS OF USE THEREOF
    Publication number: 20210355112
    Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.
    Type: Application
    Filed: May 25, 2021
    Publication date: November 18, 2021
    Applicant: ALIGOS THERAPEUTICS, INC.
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard RABOISSON, David McGowan, Jerome Deval
  • CAPSID ASSEMBLY MODULATOR DOSING REGIMEN
    Publication number: 20210260025
    Abstract: The present disclosure is directed to methods of using a capsid assembly inhibitor for the treatment of hepatitis B virus infection.
    Type: Application
    Filed: March 16, 2021
    Publication date: August 26, 2021
    Inventors: Koen VANDYCK, Oliver LENZ, Claire Elisabeth BALMAIN, Jan SNOEYS, Joris Jozef VANDENBOSSCHE, Dominique Josiane W. VERSTRAETE, Jeysen Zivan YOGARATNAM, Maria JANSENS, Frederic VAN DYCKE
  • Modulators of THR-? and methods of use thereof
    Patent number: 11091467
    Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: August 17, 2021
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, David McGowan, Jerome Deval
  • Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
    Patent number: 11078193
    Abstract: Inhibitors of HBV replication of Formula (A) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R5 to R6 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: August 3, 2021
    Assignee: Janssen Sciences Ireland UC
    Inventors: Koen Vandyck, Geerwin Yvonne Paul Haché, Stefaan Julien Last, Geert Rombouts, Wim Gaston Verschueren, Pierre Jean-Marie Bernard Raboisson
  • CYCLIZED SULFAMOYLARYLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
    Publication number: 20210179635
    Abstract: Inhibitors of HBV replication of Formula (I-A) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 17, 2021
    Inventors: Sandrine Marie Helene VENDEVILLE, Stefaan Julien LAST, Samuël Dominique DEMIN, Sandrine Céline GROSSE, Geerwin Yvonne Paul HACHÉ, Lili HU, Serge Maria Aloysius PIETERS, Geert ROMBOUTS, Koen VANDYCK, Wim Gaston VERSCHUEREN, Pierre Jean-Marie Bernard RABOISSON
  • Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
    Patent number: 10995064
    Abstract: Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: May 4, 2021
    Assignee: JANSSEN SCIENCES IRELAND UC
    Inventors: Koen Vandyck, Stefaan Julien Last, Geert Rombouts, Wim Gaston Verschueren, Pierre Jean-Marie Bernard Raboisson
  • Capsid assembly modulator dosing regimen
    Patent number: 10973801
    Abstract: The present disclosure is directed to methods of using a capsid assembly inhibitor for the treatment of hepatitis B virus infection.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: April 13, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Koen Vandyck, Oliver Lenz, Claire Elisabeth Balmain, Jan Snoeys, Joris Jozef Vandenbossche, Dominique Josiane W. Verstraete, Jeysen Zivan Yogaratnam, Maria Jansens, Frederic Van Dycke
  • Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
    Patent number: 10941113
    Abstract: Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R1, R2, R3 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: March 9, 2021
    Assignee: Janssen Sciences Ireland UC
    Inventors: Koen Vandyck, Stefaan Julien Last, Pierre Jean-Marie Bernard Raboisson
  • SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
    Publication number: 20210024462
    Abstract: Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Application
    Filed: October 7, 2020
    Publication date: January 28, 2021
    Inventors: Koen VANDYCK, Stefaan Julien LAST, Geert ROMBOUTS, Wim Gaston VERSCHUEREN, Pierre Jean-Marie Bernard RABOISSON
  • Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
    Patent number: 10875876
    Abstract: Inhibitors of HBV replication of Formula (I-A) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: December 29, 2020
    Assignee: JANSSEN SCIENCES IRELAND UC
    Inventors: Sandrine Marie Helene Vendeville, Stefaan Julien Last, Samuël Dominique Demin, Sandrine Céline Grosse, Geerwin Yvonne Paul Haché, Lili Hu, Serge Maria Aloysius Pieters, Geert Rombouts, Koen Vandyck, Wim Gaston Verschueren, Pierre Jean-Marie Bernard Raboisson
  • MODULATORS OF THR-BETA AND METHODS OF USE THEREOF
    Publication number: 20200354345
    Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.
    Type: Application
    Filed: May 7, 2020
    Publication date: November 12, 2020
    Applicant: ALIGOS THERAPEUTICS, INC.
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard RABOISSON, David McGowan, Jerome Deval
  • COMPOUNDS TARGETING PRMT5
    Publication number: 20200317686
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 31, 2020
    Publication date: October 8, 2020
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
  • SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
    Publication number: 20200255373
    Abstract: Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Application
    Filed: April 24, 2020
    Publication date: August 13, 2020
    Inventors: Koen VANDYCK, Stefaan Julien LAST, Geert ROMBOUTS, Wim Gaston VERSCHUEREN, Pierre Jean-Marie Bernard RABOISSON
  • Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
    Patent number: 10676429
    Abstract: Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: June 9, 2020
    Assignee: Janssen Sciences Ireland UC
    Inventors: Koen Vandyck, Stefaan Julien Last, Geert Rombouts, Wim Gaston Verschueren, Pierre Jean-Marie Bernard Raboisson
  • Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis
    Patent number: 10654837
    Abstract: Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them, alone or in combination with other drugs, in fibrosis and/or cirrhosis prevention or therapy.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: May 19, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Zhao-Kui Wan, Haibing Guo, Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
    Publication number: 20200039931
    Abstract: Inhibitors of HBV replication of Formula (ID) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, Ra to Rd and R4 to R6 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Application
    Filed: October 14, 2019
    Publication date: February 6, 2020
    Inventors: Koen VANDYCK, Geerwin Yvonne Paul HACHÉ, Stefaan Julien LAST, David Craig MCGOWAN, Geert ROMBOUTS, Wim Gaston VERSCHUEREN, Pierre Jean-Marie Bernard RABOISSON
  • SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS
    Publication number: 20190345145
    Abstract: Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them, alone or in combination with other drugs, in fibrosis and/or cirrhosis prevention or therapy.
    Type: Application
    Filed: February 6, 2018
    Publication date: November 14, 2019
    Inventors: Zhao-Kui WAN, Haibing GUO, Koen VANDYCK, Pierre Jean-Marie Bernard RABOISSON, Abdellah TAHRI
  • Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
    Patent number: 10457638
    Abstract: Inhibitors of HBV replication of Formula (ID) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, Ra to Rd and R4 to R6 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: October 29, 2019
    Assignee: Janssen Sciences Ireland UC
    Inventors: Koen Vandyck, Geerwin Yvonne Paul Haché, Stefaan Julien Last, David Craig McGowan, Geert Rombouts, Wim Gaston Verschueren, Pierre Jean-Marie Bernard Raboisson
  • Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
    Patent number: 10450270
    Abstract: Inhibitors of HBV replication of Formula (IA) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X and R1 to R6 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: October 22, 2019
    Assignee: Janssen Sciences Ireland UC
    Inventors: Koen VanDyck, Bart Rudolf Romanie Kesteleyn, Serge Maria Aloysius Pieters, Geert Rombouts, Wim Gaston Verschueren, Pierre Jean-Marie Bernard Raboisson